Gliuxil 200 ml.


Manufacturer: Ukraine

To ensure the body’s caloric needs in the framework of partial and partial parenteral nutrition, to reduce intoxication, correct the acid-base balance in shock conditions (taking into account the osmolarity of blood and urine), with burn disease, with prolonged purulent processes, with liver diseases, with various infectious diseases and toxicoinfections, in the postoperative period.



Gliuxil Storage:

active substances: 1 ml of solution contains glucose 75 mg, xylitol 50 mg, sodium acetate trihydrate 4.98 mg, sodium chloride 2.88 mg, calcium chloride dihydrate (in terms of calcium chloride) 0.1 mg, potassium chloride 0.45 mg, magnesium chloride hexahydrate 0.43 mg;


water for injections.

Gliuxil Dosage form.

Solution for infusion.

Main physical and chemical properties: clear colorless or yellowish liquid. The ionic composition of the drug: Na + – 85.9 mmol / l, K + – 6.0 mmol / l, Ca ++ – 0.9 mmol / l, Mg ++ – 2.1 mmol / l, Cl- – 61.3 mmol / l, CH3COO- – 36.6 mmol / l.

Pharmacotherapeutic group.

Blood substitutes and perfusion solutions. Electrolytes in combination with other drugs.

ATX code B05X A31.

Gliuxil Pharmacological properties.


Gluxil® has energetic, detoxifying, rheological, anti-shock and alkalizing effects.

The main active ingredients in the drug are glucose, xylitol and sodium acetate.

Glucose is not only the main source of energy in the body, but also a necessary component for the synthesis of a number of substances. The most important is protein metabolism.

Xylitol is a five-atom alcohol that, when administered intravenously, is rapidly incorporated into the overall metabolism. Xylitol, unlike fructose and sorbitol, does not cause a decrease in liver adenine nucleotides (ATP, ADP, AMP), it is safe for administration to patients who are sensitive to fructose or deficiency of the enzyme fructose-1,6-diphosphatase. Xylitol is thought to have a greater antiketogenic, nitrogen-retaining effect than glucose, and is equally well absorbed in both the pre- and postoperative periods. Given that xylitol is a source of energy with non-insulin-dependent metabolism, antiketogenic and lipotropic, it is recommended for use as a means of parenteral nutrition in patients, especially those who have undergone operations on the gastrointestinal tract.


Glucose is metabolized in all cells and is the most important source of energy primarily for the brain, erythrocytes and bone marrow cells. It is important that glucose is utilized even under anaerobic conditions. The maximum rate of glucose utilization by the body is 0.5 g / h.

The product of carbohydrate metabolism – xylitol – is pentitol and is directly included in the pentose phosphate cycle of metabolism. 80% of xylitol is absorbed by the liver and accumulates as glycogen, the rest of xylitol is absorbed by tissues of other organs (kidneys, heart, pancreas, adrenal glands, brain) and excreted in the urine. The maximum rate of xylitol utilization is 0.25 g / kg body weight / hour.

Clinical characteristics.


To meet the body’s need for calories in partial and partial parenteral nutrition, to reduce intoxication, correction of acid-base balance in shock (taking into account the osmolarity of blood and urine), burn disease, prolonged purulent processes, liver disease, various infectious diseases and toxicoinfections, in the postoperative period.


Hypersensitivity to the components of the drug. Diabetes mellitus and conditions accompanied by hyperglycemia, hyperkalemia, hypercoagulation, hyperosmolar coma, anuria. Gluxil® should not be administered in cases where fluid infusion is contraindicated (edema, hemorrhage into the brain, thromboembolism, severe cardiovascular decompensation, hypertension of III degree).